In a decision issued by the Federal Circuit on October 24, 2018, the court affirmed a finding by the Patent Trial and Appeal Board (PTAB) that a multiple sclerosis (MS) treatment claimed in an application owned by FWP IP APS (FWP) was not supported by adequate written description under 35 U.S.C. § 112. While the
Jessica Zurlo is an associate in the Intellectual Property Practice Group, and her practice is focused on patent law and competitive practices litigation. She is registered to practice before the U.S. Patent and Trademark Office, and assists foreign and domestic clients in patent preparation, prosecution, opinion work, and enforcement.
Patent Registration Number: 71,693